Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer


ŞANLI Y., Zukotynski K., Mittra E., Chen D. L., Nadel H., Niederkohr R. D., ...More

CLINICAL NUCLEAR MEDICINE, vol.43, no.12, 2018 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 43 Issue: 12
  • Publication Date: 2018
  • Doi Number: 10.1097/rlu.0000000000002247
  • Journal Name: CLINICAL NUCLEAR MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: head and neck cancer, PET, CT, PET, MR, SQUAMOUS-CELL CARCINOMA, POSITRON-EMISSION-TOMOGRAPHY, METABOLIC TUMOR VOLUME, DIFFUSION-WEIGHTED MRI, LYMPH-NODE METASTASES, LOCALLY ADVANCED HEAD, UNKNOWN PRIMARY SITE, FDG PET, F-18-FDG PET/CT, HUMAN-PAPILLOMAVIRUS
  • Istanbul University Affiliated: No

Abstract

There are recent advances, namely, a standardized method for reporting therapy response (Hopkins criteria), a multicenter prospective cohort study with excellent negative predictive value of F-18-FDG PET/CT for N0 clinical neck, a phase III multicenter randomized controlled study establishing the value of a negative posttherapy F-18-FDG PET/CT for patient management, a phase II randomized controlled study demonstrating radiation dose reduction strategies for human papilloma virus-related disease, and Food and Drug Administration approval of nivolumab for treatment of recurrent head and neck squamous cell carcinoma.